Haematology

Santa Maria Nuova, Italy

Haematology

Santa Maria Nuova, Italy

Time filter

Source Type

LACHEN, Suíça--(BUSINESS WIRE)--A Octapharma anunciou novos dados clínicos positivos em 66 pacientes com hemofilia A (HA) grave tratados previamente (PTPs) submetidos à profilaxia personalizada orientada por PK com Nuwiq® de acordo com o Método NuPreviq. Os dados do estudo NuPreviq (GENA-21, NCT01863758) foram publicados on-line em abril de 2017 como um artigo Early View na revista médica de renome internacional Haemophilia. O estudo NuPreviq foi iniciado em agosto de 2013 com o objetivo de desenvolver um serviço totalmente personalizado para pacientes com HA submetidos à terapia profilática. O objetivo da Octapharma é melhorar as experiências de tratamento do paciente, reconhecendo que nenhum paciente com HA é igual, portanto, uma “abordagem única para todos” para a profilaxia não é ideal. O estudo NuPreviq investigou uma nova abordagem, permitindo que o regime de tratamento do Nuwiq® fosse adaptado às necessidades específicas de cada paciente. O Método NuPreviq mede e perfila a resposta farmacocinética de cada paciente ao tratamento, o que permite que a dose de Nuwiq® seja personalizada de acordo com as circunstâncias específicas desse paciente. Os resultados do estudo mostraram que esta abordagem de profilaxia personalizada foi muito eficaz na prevenção de hemorragias, reduzindo a frequência da dose e a quantidade necessária de Nuwiq®. Mais de 80% dos pacientes não apresentaram hemorragia espontânea durante os seis meses de profilaxia personalizada com Nuwiq®. Mais de metade dos pacientes receberam infusões duas vezes por semana – ou menos – e os requisitos de dose foram reduzidos em 7%. Um estudo de extensão em andamento (GENA-21b, NCT02256917) irá avaliar ainda mais a eficácia e a segurança a longo prazo da profilaxia personalizada com Nuwiq®. Larisa Belyanskaya, chefe de IBU Haematology na Octapharma, disse: “Estamos muito entusiasmados com os resultados do estudo NuPreviq e satisfeitos que os dados do estudo GENA-21 que agora estão disponíveis ao público em geral na revista especializada Haemophilia. O estudo mostra que a profilaxia personalizada com Nuwiq® proporciona excelente proteção contra a hemorragia, extensão do intervalo de dose para a maioria dos pacientes e redução da dose. Esses dados diferenciam ainda mais o Nuwiq® de outros produtos no mercado.” Olaf Walter, membro do conselho da Octapharma, comentou que “a principal motivação da Octapharma está na prestação de serviço dedicado aos pacientes. Desenvolver um pacote de cuidados customizados que oferece uma terapêutica flexível de FVIII, verdadeiramente personalizado para atender às necessidades e estilo de vida do paciente, tem sido um objetivo da empresa e hoje podemos comemorar esta publicação dos dados clínicos extremamente positivos do NuPreviq”. Sobre os estudos GENA-21 e GENA-21b: Os estudos GENA-21 e GENA-21b, com início em agosto de 2013 e março de 2015, respectivamente, são estudos prospectivos, abertos, multicêntricos, de Fase 3b que avaliam a segurança e a eficácia da profilaxia personalizada orientada por PK com Nuwiq® em pacientes adultos com HA grave tratados previamente. Os estudos são realizados em 29 locais de estudo no mundo todo. Sobre o Nuwiq®: O Nuwiq® é uma proteína rFVIII de 4a geração, de ação natural, de longa duração, produzida em uma linha celular humana sem modificação química ou fusão com qualquer outra proteína. O Nuwiq® é cultivada sem aditivos de origem humana ou animal, é desprovida de epítopos antigênicos de proteínas não humanas e tem uma elevada afinidade para o fator de coagulação de von Willebrand. A terapêutica com Nuwiq® foi avaliada em sete ensaios clínicos concluídos que incluíram 201 pacientes tratados previamente (190 indivíduos) com HA grave, incluindo 59 crianças. O Nuwiq® é aprovado para uso no tratamento e profilaxia do sangramento em todas as faixas etárias de pacientes tratados previamente com hemofilia A na União Europeia, EUA, Canadá, Austrália, América Latina e Rússia. Outras propostas mundiais para o Nuwiq® estão sendo planejadas. Sobre a Hemofilia A: A hemofilia A é uma doença hereditária ligada ao cromossomo X causada pela deficiência de FVIII que, se não tratada, provoca hemorragias nos músculos e articulações e, consequentemente, artropatia e morbidade grave. O tratamento profilático de reposição do FVIII reduz o número de episódios de sangramento e o risco de lesões articulares permanentes. Este distúrbio afeta um em cada 5 mil a 10 mil homens em todo o mundo e 75% dos casos de hemofilia não são diagnosticados ou tratados. O desenvolvimento de anticorpos que neutralizam o FVIII (inibidores do FVIII) contra o FVIII injetado representa a complicação mais séria do tratamento. O risco cumulativo de desenvolvimento de inibidores do FVIII é de até 39% dos casos. Com sede em Lachen, Suíça, a Octapharma é uma das maiores fabricantes de proteína humana no mundo, desenvolvendo e produzindo proteínas humanas a partir do plasma humano e linhas de células humanas. Como uma empresa familiar, a Octapharma acredita no investimento para fazer diferença nas vidas das pessoas – e vem fazendo isto desde 1983, pois está no nosso sangue. O texto no idioma original deste anúncio é a versão oficial autorizada. As traduções são fornecidas apenas como uma facilidade e devem se referir ao texto no idioma original, que é a única versão do texto que tem efeito legal.


LACHEN, Switzerland--(BUSINESS WIRE)--Octapharma announces positive new clinical data in 66 previously treated patients (PTPs) with severe haemophilia A (HA) undergoing PK-guided personalized prophylaxis with Nuwiq® according to the NuPreviq Approach. Data from the NuPreviq study (GENA-21, NCT01863758) were published online in April 2017 as an Early View article in the internationally renowned medical journal, Haemophilia. The NuPreviq study was initiated in August 2013 with the aim of developing a fully personalized service for HA patients undergoing prophylactic therapy. Octapharma’s aim is to improve patient treatment experiences by recognizing that no two HA patients are the same, therefore a “one size fits all” approach to prophylaxis is not ideal. The NuPreviq study investigated a novel approach, allowing the Nuwiq® treatment regimen to be adapted to the specific needs of each individual patient. The NuPreviq Approach measures and profiles each individual patient’s pharmacokinetic response to treatment, which then allows the dosing of Nuwiq® to be personalized according to the specific circumstances of that patient. The results of the study showed that this personalized prophylaxis approach was very effective at preventing bleeds, while reducing the frequency of dosing and the amount of Nuwiq® needed. Over 80% of patients did not experience a spontaneous bleed during the 6 months of personalized prophylaxis with Nuwiq®. More than half of the patients received infusions twice a week or less, and dose requirements were reduced by 7%. An ongoing extension study (GENA-21b, NCT02256917) will further evaluate the long-term efficacy and safety of personalized prophylaxis with Nuwiq®. Larisa Belyanskaya, Head of IBU Haematology at Octapharma, said: “We are very excited by the results of the NuPreviq study and pleased that the GENA-21 study data are now available to the wider public in the specialist peer-reviewed publication, Haemophilia. The study shows that personalized prophylaxis with Nuwiq® provides excellent bleeding protection, extension of the dosing interval for most patients, and a reduction in dose. These data further differentiate Nuwiq® from other products on the market.” Olaf Walter, Board Member at Octapharma, commented that “Octapharma’s principal motivation lies with providing dedicated service to our patients. Developing a custom care package which offers flexible FVIII therapy, truly personalized to suit their needs and lifestyle, has long been a goal of the company and we celebrate today this landmark publication of the extremely positive NuPreviq clinical data.” Octapharma would like to thank everyone involved in the study, in particular the patients and their families, without whom this research would not be possible. About GENA-21 and GENA-21b studies: The GENA-21 and GENA-21b studies, initiated in August 2013 and March 2015, respectively, are prospective, open-label, multicentre, Phase 3b studies assessing the safety and efficacy of PK-guided personalized prophylaxis with Nuwiq® in previously treated adult patients with severe HA. The studies are each conducted across 29 study locations worldwide. About Nuwiq®: Nuwiq® is a naturally long-acting, 4th generation rFVIII protein, produced in a human cell line without chemical modification or fusion with any other protein. Nuwiq® is cultured without additives of human or animal origin, is devoid of antigenic non-human protein epitopes and has a high affinity for the von Willebrand coagulation factor. Nuwiq® treatment has been assessed in seven completed clinical trials which included 201 PTPs (190 individuals) with severe HA, including 59 children. Nuwiq® is approved for use in the treatment and prophylaxis of bleeding across all age groups of PTPs with haemophilia A in the EU, US, Canada, Australia, Latin America and Russia. Further worldwide submissions for Nuwiq® are planned. About haemophilia A: Haemophilia A is an X-linked hereditary disorder caused by FVIII deficiency which, if left untreated, leads to haemorrhages in muscles and joints and consequently to arthropathy and severe morbidity. FVIII replacement prophylactic treatment reduces the number of bleeding episodes and the risk of permanent joint damage. This disorder affects one in every 5,000 to 10,000 men worldwide. Globally, 75% of haemophilia cases are left undiagnosed or untreated. The development of neutralizing FVIII antibodies (FVIII inhibitors) against infused FVIII represents the most serious treatment complication. The cumulative risk of FVIII inhibitor development is reported to be currently up to 39%. Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. As a family-owned company, Octapharma believes in investing to make a difference in people’s lives and has been doing so since 1983; because it’s in our blood. In 2016, the Group achieved €1.6 billion in revenue, an operating income of €383 million and invested €249 million to ensure future prosperity. Octapharma employs more than 7,100 people worldwide to support the treatment of patients in 113 countries with products across three therapeutic areas: Octapharma owns six state-of-the-art production facilities in Austria, France, Germany, Mexico and Sweden.


News Article | May 4, 2017
Site: news.europawire.eu

More than 3,000 medical laboratory industry professionals expected to attend the launch edition of MEDLAB Europe at the Barcelona Congress Centre in Spain Barcelona, Spain, 04-May-2017 — /EuropaWire/ — After many years of operating successful MEDLAB events around Africa, Asia and the Middle East, Informa Life Sciences Exhibitions, the worlds leading publishing and exhibitions company, has announced that the MEDLAB Series will be expanding its presence into Europe. Taking place at the Barcelona Congress Centre in Barcelona, Spain, from 13-15 September 2017, more than 3,000 industry professionals are expected to attend Europe’s leading event for laboratory management and diagnosis. With the European In-Vitro Diagnostics (IVD) market expected to reach USD 15.5 billion by 2024, a platform such as MEDLAB presents a huge opportunity for global laboratory industry leaders, including manufacturers, dealers and distributors, to make inroads into the European market. Housing international exhibitors and covering 2,000 sqm of exhibition space, MEDLAB Europe will give visitors from across the world an opportunity to access cutting-edge laboratory products, next-generation technology, innovative services and world-class educational content. According to Tom Coleman, Group Exhibition Director, MEDLAB Series: “The launch of MEDLAB Europe is in line with our global expansion strategy for our MEDLAB series of events. The increasing prevalence of chronic diseases, rising geriatric population coupled with the rising awareness towards early diagnosis, has positioned the European IVD and medical laboratory market as a critical market for manufacturers, services providers, and dealers and distributors from across the globe. MEDLAB Europe will generate substantial value for our customers and partners by driving further product innovation and deeper engagement in these specific markets.” Over the four-day event, MEDLAB Europe will also offer a multi-disciplinary congress tackling current challenges and developments key to the European market, and leveraging the true potential of laboratory testing to dramatically improve patient outcomes across the continent. The conference programme covers five main tracks including Point of Care Testing (POCT), Histopathology, Lab Management, Microbiology and Haematology. From new methods of effective lab management to the development of techniques in detecting diseases, the conferences will also review the expanding role of the laboratory medicine and discuss partnership between a clinician and a lab professional in providing delivery of care to every patient. “The scientific programme at MEDLAB has been carefully designed in collaboration with some of the brightest minds in the medical laboratory industry in order to have a real impact on improving the health and wellbeing of patients across the region,” said Coleman. For more information about the MEDLAB Europe Exhibition & Congress, please visit: www.medlabeurope.com.


News Article | May 4, 2017
Site: www.24-7pressrelease.com

BARCELONA, SPAIN, May 04, 2017-- After many years of operating successful MEDLAB events around Africa, Asia and the Middle East, Informa Life Sciences Exhibitions, the worlds leading publishing and exhibitions company, has announced that the MEDLAB Series will be expanding its presence into Europe. Taking place at the Barcelona Congress Centre in Barcelona, Spain, from 13-15 September 2017, more than 3,000 industry professionals are expected to attend Europe's leading event for laboratory management and diagnosis With the European In-Vitro Diagnostics (IVD) market expected to reach USD 15.5 billion by 2024 , a platform such as MEDLAB presents a huge opportunity for global laboratory industry leaders, including manufacturers, dealers and distributors, to make inroads into the European market. Housing international exhibitors and covering 2,000 sqm of exhibition space, MEDLAB Europe will give visitors from across the world an opportunity to access cutting-edge laboratory products, next-generation technology, innovative services and world-class educational content.According to Tom Coleman, Group Exhibition Director, MEDLAB Series: "The launch of MEDLAB Europe is in line with our global expansion strategy for our MEDLAB series of events. The increasing prevalence of chronic diseases, rising geriatric population coupled with the rising awareness towards early diagnosis, has positioned the European IVD and medical laboratory market as a critical market for manufacturers, services providers, and dealers and distributers from across the globe. MEDLAB Europe will generate substantial value for our customers and partners by driving further product innovation and deeper engagement in these specific markets."Over the four-day event, MEDLAB Europe will also offer a multi-disciplinary congress tackling current challenges and developments key to the European market, and leveraging the true potential of laboratory testing to dramatically improve patient outcomes across the continent.The conference programme covers five main tracks including Point of Care Testing (POCT), Histopathology Microbiology and Haematology . From new methods of effective lab management to the development of techniques in detecting diseases, the conferences will also review the expanding role of the laboratory medicine and discuss partnership between a clinician and a lab professional in providing delivery of care to every patient."The scientific programme at MEDLAB has been carefully designed in collaboration with some of the brightest minds in the medical laboratory industry in order to have a real impact on improving the health and wellbeing of patients across the region," said Coleman.For more information about the MEDLAB Europe Exhibition & Congress, please visit: www.medlabeurope.com Informa Life Sciences Exhibitions, in charge of the healthcare portfolio within Informa's Global Exhibitions division, organises 26 exhibitions yearly covering the Middle East, Africa, Asia, Europe and US market, connecting more than 150,000 healthcare professionals worldwide and offering a range of marketing solutions for companies involved with the healthcare sector. Over 100 congresses take place in parallel with the exhibitions.Informa Life Sciences Exhibitions publishes four international healthcare magazines, offers Dothealth, a healthcare portal showcasing over 40,000 healthcare companies and runs Healthy Change, an online recruitment portal.


News Article | April 27, 2017
Site: www.eurekalert.org

Research led by University of Leicester and University Hospitals of Leicester NHS Trust reveals 'transformative outcomes' for patients with chronic lymphocytic leukemia "We are proud to be part of this study. Our long term follow up of previously treated patients shows maintained efficacy without toxicity. This study is the first report of long term follow-up of selective BTK inhibitors in patients with chronic lymphocytic leukaemia - and it is excellent news for patients." Scientists have described new results of a blood cancer study as 'outstanding' in tackling previously untreatable forms of chronic lymphocytic leukaemia (CLL). The advance led by a team from the University of Leicester and University Hospitals of Leicester NHS Trust, within the Hope Clinical Trials Facility, focused on treating patients with CLL. It follows on from a world-first clinical trial of a new drug to treat particular blood cancers. Results of that international clinical trial, led by Dr Harriet Walter and Professor Martin Dyer were published in the journal Blood in November 2015 and looked at the efficacy of a new inhibitor, ONO/GS-4059, in the treatment of CLL and Non-Hodgkin Lymphoma patients, refractory or resistant to current chemotherapies. ONO/GS-4059 targets BTK, a protein essential for the survival and proliferation of the tumour cells. The study opened in January 2012 and 90 patients were enrolled in different centres in the UK and in France, with 28 coming from Leicester. Patients with CLL showed the best response and most of them were still on the study after 3 years, and remarkably without notable toxicities. In the new paper, the researchers are reporting for the long-term follow-up results. Their work, published in the journal Blood, was funded by the Ernest and Helen Scott Haematological Research Institute, ONO Pharmaceuticals, Gilead Pharmaceuticals and the Cancer Research UK Leicester Experimental Cancer Medicine Centre. Local charity Hope Against Cancer fund the Clinical Trials Facility based at the Leicester Royal Infirmary. Professor Martin Dyer is Professor of Haemato-Oncology in the Department of Cancer Studies at the University of Leicester and Honorary Consultant Physician in the Department of Haematology at Leicester Royal Infirmary. He said: "This current paper describes the long term follow up and shows that in patients with CLL the remissions are durable and associated with no new toxicities. Furthermore, in collaboration with Sistemas Genomicos, a company in Valencia, we have shown that mutations associated with aggressive disease respond well to treatment with ONO/GS-4059. "Our long term follow up shows maintained efficacy without toxicity. This study is the first report of long term follow-up of a selective BTK inhibitor - and it is excellent news for patients. "The results we are presenting are based on an international clinical study involving the UK, France, Japan and US - and led by Leicester. This was a Phase 1 clinical study which means the researchers are in the early stages of testing the drug's effectiveness. "We are now doing studies of ONO/GS-4059 in combination with other precision medicines to assess whether these results can be enhanced in patients with CLL and other B cell malignancies." Local cancer research charity, Hope Against Cancer, has been funding some of Professor Dyer's work. Chief Executive of the charity, Nigel Rose said: "Professor Dyer is a long-standing collaborator and recipient of Hope's funding. We are delighted that this is being put to such extremely important use in meeting our charity's mission of improving the lives of cancer patients locally."


News Article | February 15, 2017
Site: globenewswire.com

Helsinn Provides Grant for ESMO's Preceptorship Course on Supportive and Palliative Care Lugano, Switzerland, February 15, 2017 - Helsinn, a Swiss pharmaceutical group focused on building quality cancer care, announces that the Group has provided a grant to the European Society for Medical Oncology ("ESMO") for a preceptorship event dedicated to supportive and palliative care for physicians. The preceptorship course will take place in Zurich on February 20-21, 2017 and will touch on a broad range of aspects related to cancer supportive and palliative care. The key learning objectives of the preceptorship are to: The Chair of the event will be Dr Florian Strasser MD, Associate Professor in the Clinic Oncology/Hematology at the Cantonal Hospital St. Gallen, Head of Oncological Palliative Medicine at Cantonal Hospital St Gallen, Switzerland, where he is responsible for the clinical and research activities in Palliative Oncology and in Geriatric Oncology. He is also substantially involved in Geriatric Oncology, Supportive Care and Cancer Rehabilitation for both in- and out-patients in the Comprehensive Cancer Center. The co-Chair is Dr Karin Jordan who, since 2010, has been Associate Professor of Medical Oncology and Supportive Care in the Department of Oncology/Haematology at the University Hospital, Halle, and who has just recently changed position and is now working at the University of Heidelberg. The event is expected to be attended by members of ESMO from around the world. The aim of these educational courses, which focus on teaching standard of care in specific areas, is to provide "state of the art" lectures in an interactive setting including formal presentations and interaction between experts and attendees presenting clinical cases. The full meeting program is available here. Sergio Cantoreggi, Helsinn Group Chief Scientific Officer, said: "At Helsinn we are delighted to be able to provide a grant to ESMO to work with physicians and further advance supportive and palliative care through this Preceptorship Course. This event will help foster relationships between senior, experienced physicians, and those at the start of their careers, meaning that patients will receive the best possible supportive care to help them live with cancer on a day to day basis." Dr Florian Strasser MD, Chair of the Preceptorship Course on Supportive and Palliative Care, commented: "I am delighted this event dedicated to both supportive and palliative care has been organized, and I thank those at Helsinn for their generous and fully unrestricted support in helping us establish this. Supportive and palliative care is an area of oncology that does not receive enough merit increasing attention in modern, personalized oncology and this event will help to address this problem." Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a broad development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Ireland and the US, a representative office in China as well as a product presence in about 90 countries globally. For more information, please visit www.helsinn.com. ESMO is the leading professional organisation for medical oncology. With 15,000 members representing oncology professionals from over 130 countries worldwide, ESMO is the society of reference for oncology education and information. We are committed to supporting our members to develop and advance in a fast-evolving professional environment.


Die positive Beurteilung des CHMP basierte auf einer Prüfung der Daten aus der „Phase-3-Studie MMY3003“ (POLLUX), die im Oktober 2016 im The New England Journal of Medicine veröffentlicht wurde,3 sowie aus der Studie „Phase-3-Studie MMY3004“ (CASTOR), im August 2016 ebenfalls im The New England Journal of Medicine veröffentlicht.4 Das Sicherheitsprofil von Daratumumab in Kombination mit Standardbehandlungsmethoden stimmte mit Montotherapiestudien überein. Bei Verabreichung von Lenalidomid in Verbindung mit Dexamethason (POLLUX) traten bei der Behandlung als häufigste Nebenwirkungen von Grad 3 oder 4 Neutropenie (51,9 %), Thrombozytopenie (12,7 %) und Anämie (12,4 %) auf.3 Die Zugabe von Daratumumab führte bei 47,7 % der Patienten zu infusionsbedingten Reaktionen, meist von Grad 1 oder 2.3 In Kombination mit Bortezomib und Dexamethason (CASTOR) wurden als die drei häufigsten Nebenwirkungen von Grad 3 oder 4 Thrombozytopenie (45,3 %), Anämie (14,4 %) und Neutropenie (12,8 %) beobachtet.4 Bei 45,3 % der Patienten zeigten sich infusionsbedingte Reaktionen infolge der Behandlung mit Daratumumab. Diese Reaktionen waren überwiegend von Grad 1 oder 2 (Grad 3 bei 8,6 % der Patienten), und bei 98,2 % der Behandelten traten die Reaktionen während der ersten Infusion auf.4 „Nahezu alle Patienten mit multiplem Myelom erleiden Rückfälle, die in der Regel immer aggressiver werden“, erläuterte Dr. Catherine Taylor, Haematology Therapeutic Area Lead, Janssen Europe, the Middle East and Africa (EMEA). „Diese wichtige und schnelle Empfehlung ermutigt mich, denn sie würdigt die Fortschritte in der Behandlung des multiplen Myeloms.“ 1. EMA. Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 February 2017. Verfügbar unter: http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/document_listing/document_listing_000378.jsp. Zuletzt aufgerufen Februar 2017. 2. American Society of Clinical Oncology. Multiple myeloma: overview. Available at: http://www.cancer.net/cancer-types/multiple-myeloma/overview Zuletzt aufgerufen November 2016. 3. Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide and dexamethasone for multiple myeloma. New Eng J Med. 2016;375:1319–1331. 4. Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib and dexamethasone for relapsed and refractory multiple myeloma. New Eng J Med. 2016;375:754–766. 5. Janssen. Janssen’s Single-Agent DARZALEX® (daratumumab) Approved by European Commission for Treatment of Multiple Myeloma (MM). Verfügbar unter: http://www.janssen.com/janssen-s-single-agent-darzalex-daratumumab-approved-european-commission-treatment-multiple-myeloma. Zuletzt aufgerufen November 2016. 10. De Angelis R, Minicozzi P, Sant M, et al. Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000-2007: results of EUROCARE-5 population-based study. Eur J Cancer. 2015;51:2254-68. 12. Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012;26:149-57. 13. Fedele G, di Girolamo M, Recine U, et al. CD38 ligation in peripheral blood mononuclear cells of myeloma patients induces release of protumorigenic IL-6 and impaired secretion of IFNgamma cytokines and proliferation. Mediat Inflamm. 2013;2013:564687. 14. Lin P, Owens R, Tricot G, et al. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol. 2004;121:482-8. 15. Santoconito AM, Consoli U, Bagnato S et al. Flow cytometric detection of aneuploid CD38++ plasmacells and CD19+ B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients. Leuk Res. 2004;28:469-77. 16. Overdijk MB, Jansen JH, Nederend M, et al. The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcy Receptor-Mediated Cross-Linking. J Immunol. 2016;197(3):807-13. 17. de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186:1840-8. 18. Overdijk MB, Verploegen S, Bögels M, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015;7:311-21. 19. Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128:384-94.


News Article | February 23, 2017
Site: www.eurekalert.org

During its 43rd Annual Meeting in Marseille, France, from 26th-29th March, the EBMT will hold a series of activities for its 5,000 delegates to celebrate 60 years of medical innovations saving patients' lives. The EBMT celebrates 60 years of medical innovations saving the lives of patients with blood cancers and other deadly diseases During its 43rd Annual Meeting in Marseille, France, from 26th-29th March, the EBMT will hold a series of activities for its 5,000 delegates to celebrate 60 years of medical innovations saving patients' lives. The EBMT will acknowledge the work that stems from the pioneering observations made by E. Donnall Thomas, also known as the father of bone marrow transplantation and who received the Nobel Prize in Medicine in 1990. For over 60 years Thomas' colleagues and fellows, not only in the United States but also in Europe and worldwide, have worked relentlessly in preclinical and clinical research to develop innovative treatments that improve the outcome and quality of life for cancer patients. This year marks the 60th anniversary of one of the seminal publications that triggered the introduction of haematopoietic stem cell transplantation (HSCT) in medical practices worldwide. This landmark paper by Thomas et al. entitled, "Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy" was published in the New England Journal on the 12th September 1957. The same year, this group also published other landmark papers in Blood. From the mid-1950s, Thomas developed methods for providing people with new bone marrow cells through transplants. Using radiation, chemotherapy, and nowadays immunosuppressive drugs, the body's own bone marrow cells are killed and the immune system's rejection mechanism is subdued. Bone marrow cells from a donor are then provided through a blood transfusion. In 1958, a year after Thomas' paper, Georges Mathé performed the first ever successful allogeneic bone marrow transplant on unrelated human beings. Since then, major developments in the field of HSCT have occurred thanks to the contributions of researchers worldwide. In fact, Nobel Prizes in physiology or medicine have been awarded for research in stem cells and transplantation: Jean Dausset, Baruj Benacerraf and Georges D. Snell in 1980 for the HLA histocompatibility system discovery; Joseph E. Murray and E. Donnall Thomas in 1990 for their discoveries concerning organ and cell transplantation for the treatment of human disease. The "EBMT's mission is very important and very ambitious," states Mohamad Mohty, President of the EBMT, and Head of the Haematology department at the Saint-Antoine Hospital in Paris. "Our goal is to conquer and cure blood diseases. In 1974, the visionary founders of the EBMT created one of the most successful medical societies in the world, and established a transplant registry that 43 years later includes 500,000 registered patients. The EBMT is in the privileged position of being always in the lead to disseminate knowledge, and advance the field of stem cell transplantation and cellular therapy" concludes Professor Mohty. While research is evolving, all eyes are turned towards novel cellular therapies for potential applications. Christian Chabannon, President of the 43rd EBMT Annual Meeting and Secretary of the Cellular Therapy and Immunobiology Working Party explains: "This denotes significant changes in the field, where medical practices evolve from the relatively monotypic approach of haematopoietic cell transplant to the more versatile use of different categories of cellular therapies." The EBMT's objective is to understand and exploit the biological, including immunological, events occurring upon HSCT at large, and to implement modern cellular therapies based on cell and gene engineering approaches to improve transplantation outcomes. At the Opening Session of the 43rd EBMT Annual Meeting, Rainer Storb from the faculty of both, the Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, will give a keynote lecture entitled, "60 years of HSCT: progress from bone marrow transplantation to the first cellular and gene therapies." The EBMT is a not-for-profit medical and scientific organisation established in 1974. It is dedicated to fighting life-threatening blood cancers and diseases and improving patients' lives. The EBMT Members--more than 4,000 physicians, nurses, scientists and other healthcare professionals--participate in a unique collaborative network of peers involved in HSCT and cellular therapy research. The membership encompasses more than 600 centres, from over 60 countries, that perform or are involved in HSCT. The EBMT holds a central role in performing co-operative studies and disseminating state-of-the-art knowledge aimed at increasing survival rates and enhancing the quality of life of patients with life-threatening blood cancers and diseases. For further information about the EBMT, please visit the website: http://www. and follow us on Twitter: @TheEBMT


In a talk focused on novel therapeutic strategies to prevent relapse, the most important cause of treatment failure after hematopoietic stem cell transplant (HSCT) in patients with hematologic malignancies, Sergio Giralt, MD, Chief of the Adult Bone Marrow Transplantation at Sloan Kettering, highlighted Actinium Pharmaceuticals' Iomab-B. The renowned physician was optimistic about the potential of adding targeted agents to the pretransplant conditioning regimen to increase the antitumor effect. Of these options, Dr. Giralt focused extensively on Actinium's lead product candidate, Iomab-B, a radiolabeled antibody-drug conjugate targeted against CD45; and rituximab, an antibody directed against CD20. Actinium's Iomab-B is a therapy designed to help prepare patients for a hematopoietic stem cell transplant. Actinium is currently conducting a single pivotal 150-patient, multicenter Phase 3 clinical study of Iomab-B in patients with relapsed or refractory acute myeloid leukemia (AML), age 55 and older. Internationally recognized, Dr. Giralt is board certified in internal medicine with subspecialties in medical oncology and hematology. He is an active member of the American Medical Association, American College of Physicians, American Society of Hematology, American Society of Clinical Oncology, North American Society of Blood and Bone Marrow Transplantation (ASBMT), International Society of Hematotherapy and Graft Engineering, International Society of Haematology, and the Gerontological Society of America. Actinium, a company founded on technology developed by MSK, continues to work closely with the world-renowned cancer center, a relationship that has only been enhanced since the company in-licensed Iomab-B. Sergio Giralt, MD, along with other leading physicians at Sloan Kettering, currently serves on the Advisory Board of Actinium Pharmaceuticals. For more information on Iomab-B and the other therapeutic candidates in Actinium's robust product pipeline visit: http://www.actiniumpharma.com/ Online Media Group, Inc. is not registered with any financial or securities regulatory authority and does not provide, nor claims to provide, investment advice or recommendations to readers of this release to buy, sell or hold any securities. Investing intrinsically involves substantial risk and readers are reminded to consult an investment professional and complete their own due diligence, including SEC filings, when researching any companies mentioned in this release. This release is based upon publicly available information and, while vetted, is not considered to be all-inclusive or guaranteed to be free from errors. With respect to Section 17(B) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that Online Media Group, Inc. may have received compensation from the companies mentioned in this release.


The strong collaboration between Actinium Pharmaceuticals and the prestigious Memorial Sloan Kettering Cancer Center (MSK) was on full display during a recent presentation at a satellite symposium to the 2017 BMT Tandem Meetings (http://www.onclive.com/conference-coverage/bmt-tandem-2017/novel-pretransplant-conditioning-regimens-seek-to-reduce-relapse-in-blood-cancers). In a talk focused on novel therapeutic strategies to prevent relapse, the most important cause of treatment failure after hematopoietic stem cell transplant (HSCT) in patients with hematologic malignancies, Sergio Giralt, MD, Chief of the Adult Bone Marrow Transplantation at Sloan Kettering, highlighted Actinium Pharmaceuticals' Iomab-B. The renowned physician was optimistic about the potential of adding targeted agents to the pretransplant conditioning regimen to increase the antitumor effect. Of these options, Dr. Giralt focused extensively on Actinium's lead product candidate, Iomab-B, a radiolabeled antibody-drug conjugate targeted against CD45; and rituximab, an antibody directed against CD20. Actinium's Iomab-B is a therapy designed to help prepare patients for a hematopoietic stem cell transplant. Actinium is currently conducting a single pivotal 150-patient, multicenter Phase 3 clinical study of Iomab-B in patients with relapsed or refractory acute myeloid leukemia (AML), age 55 and older. Internationally recognized, Dr. Giralt is board certified in internal medicine with subspecialties in medical oncology and hematology. He is an active member of the American Medical Association, American College of Physicians, American Society of Hematology, American Society of Clinical Oncology, North American Society of Blood and Bone Marrow Transplantation (ASBMT), International Society of Hematotherapy and Graft Engineering, International Society of Haematology, and the Gerontological Society of America. Actinium, a company founded on technology developed by MSK, continues to work closely with the world-renowned cancer center, a relationship that has only been enhanced since the company in-licensed Iomab-B. Sergio Giralt, MD, along with other leading physicians at Sloan Kettering, currently serves on the Advisory Board of Actinium Pharmaceuticals. For more information on Iomab-B and the other therapeutic candidates in Actinium's robust product pipeline visit: http://www.actiniumpharma.com/ Online Media Group, Inc. is not registered with any financial or securities regulatory authority and does not provide, nor claims to provide, investment advice or recommendations to readers of this release to buy, sell or hold any securities. Investing intrinsically involves substantial risk and readers are reminded to consult an investment professional and complete their own due diligence, including SEC filings, when researching any companies mentioned in this release. This release is based upon publicly available information and, while vetted, is not considered to be all-inclusive or guaranteed to be free from errors. With respect to Section 17(B) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that Online Media Group, Inc. may have received compensation from the companies mentioned in this release.

Loading Haematology collaborators
Loading Haematology collaborators